CD55, CD59, factor H and factor H-like 1 gene expression analysis in tumors of the ovary and corpus uteri origin.
The expression level of complement regulators in ovarian and corpus uteri tumors was not fully established so far. In current manuscript we performed gene expression analysis by the real-time PCR approach to investigate both membrane bound - CD55 and CD59 and fluid phase - factor H and factor H-like 1 complement regulators. We found increased CD55 expression in corpus uteri tumors when compared to control tissues, whereas in ovarian cancer CD55 expression was lower than in control sections. Additionally we found CD59 expression to be more prominent in ovarian cancer than in corpus uteri tumor samples. We observed also the strong positive correlation between the level of expression of the whole group of regulators, which was particularly significant between the expression of factor H and factor H- like 1. In conclusion we present novel results which implicates different role of particular complement inhibitors in the regulation of the complement system in two cancer types examined. Strong positive correlation between examined proteins implicates similar pattern of the regulation which should be taken into consideration with regards to the possible immunotherapy applied as adjuvant therapeutic approach in these two indications. The inhibition of complement regulation may serve as a strategy to potentiate the efficacy of such treatment.
Department of Medical Biology and Translational Research, University of Information Technology and Management, Faculty of Medicine, Sucharskiego Street 2, 35-225 Rzeszow, Poland; Department of Molecular Biology and Translational Research, Institute of Rural Health, Jaczewskiego Street 2, 20-090 Lublin, Poland.
L
L
Kapka-Skrzypczak
Department of Pathology, Medical University of Warsaw, Pawinskiego Street 7, 02-091 Warsaw, Poland. Electronic address: ewa.wilczek@wum.edu.pl.
E
E
Wolinska
Department of Pathology, Medical University of Warsaw, Pawinskiego Street 7, 02-091 Warsaw, Poland.
G
G
Szparecki
Laboratory of Molecular and Systemic Neuromorphology, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteura Street 3, 02-091 Warsaw, Poland.
G M
GM
Wilczynski
Department of Molecular Biology and Translational Research, Institute of Rural Health, Jaczewskiego Street 2, 20-090 Lublin, Poland.
M
M
Czajka
Second Department of Gynecology, Medical University of Lublin, Jaczewskiego Street 8, 20-954 Lublin, Poland.
M
M
Skrzypczak
D018958:CD55 Antigens / Q000235:genetics*; D018957:CD59 Antigens / Q000235:genetics*; D016022:Case-Control Studies; D003180:Complement C3b Inactivator Proteins / Q000235:genetics*; D017242:Complement Factor H / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D020869:Gene Expression Profiling; D006801:Humans; D010051:Ovarian Neoplasms / Q000235:genetics*; D014594:Uterine Neoplasms / Q000235:genetics*
D018958:CD55 Antigens; D018957:CD59 Antigens; C517621:CFHR1 protein, human; D003180:Complement C3b Inactivator Proteins; D017242:Complement Factor H
CD55; CD59; Factor H; Factor H-like 1; Gynecological cancer